Yi He Ling
Impact in
- Oncology top 10%
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- Hematology top 10%
- Multiple Myeloma Research and Treatments
Papers in
- Oncology 9
- Cancer-related Molecular Pathways 5
- Peptidase Inhibition and Analysis 3
- Cancer Treatment and Pharmacology 1
-
- Cancer therapeutics and mechanisms 3
- Ubiquitin and proteasome pathways 3
- Co-authors
- Román Pérez-Soler (11 shared papers)Waldemar Priebe (3 shared papers)Adel K. El‐Naggar (1 shared paper)Leonard Liebes (2 shared papers)Franco M. Muggia (2 shared papers)Jian Jiang (2 shared papers)Julian Adams (2 shared papers)Peter J. Elliott (2 shared papers)
- Journals
- Molecular Pharmacology (1 paper)The Journal of Steroid Biochemistry and Molecular Biology (1 paper)Cell Research (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)European Journal of Cancer (1 paper)
- Partner nations
- United StatesChinaSwitzerland
In The Last Decade
Yi He Ling
15 papers receiving 833 citations
Peers
Comparison fields: 5 of 88
- Oncology 381
- Hematology 111
- Molecular Biology 580
- Cancer Research 113
- Toxicology 25
Countries citing papers authored by Yi He Ling
This map shows the geographic impact of Yi He Ling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi He Ling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi He Ling more than expected).
Fields of papers citing papers by Yi He Ling
This network shows the impact of papers produced by Yi He Ling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi He Ling. The network helps show where Yi He Ling may publish in the future.
Co-authors
The 25 scholars most cited alongside Yi He Ling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. | 2003 | 225 |
| 2 | 1996 | 190 | |
| 3 | PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. | 2002 | 161 |
| 4 | Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. | 2000 | 63 |
| 5 | Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. | 1994 | 45 |
| 6 | Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells. | 1998 | 39 |
| 7 | 2009 | 33 | |
| 8 | 2007 | 27 | |
| 9 | Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells. | 2000 | 18 |
| 10 | Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. | 1993 | 17 |
| 11 | 2008 | 12 | |
| 12 | 1994 | 12 | |
| 13 | Exogenous expression of H-cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expression. | 2004 | 11 |
| 14 | 2016 | 1 | |
| 15 | 2015 | 1 |
About Yi He Ling
Yi He Ling is a scholar working on Oncology, Molecular Biology, Genetics, Biotechnology and Otorhinolaryngology, having authored 15 papers that have together received 855 indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (5 papers), Cancer therapeutics and mechanisms (3 papers), Ubiquitin and proteasome pathways (3 papers), Peptidase Inhibition and Analysis (3 papers), Cancer Research and Treatments (2 papers), Estrogen and related hormone effects (2 papers), Microtubule and mitosis dynamics (1 paper) and Cancer Treatment and Pharmacology (1 paper). The work is most often cited by research in Oncology (381 citations), Hematology (111 citations), Molecular Biology (580 citations), Cancer Research (113 citations) and Toxicology (25 citations). Yi He Ling has collaborated with scholars based in United States, China and Switzerland. Frequent co-authors include Román Pérez-Soler, Waldemar Priebe, Adel K. El‐Naggar, Leonard Liebes, Franco M. Muggia, Jian Jiang, Julian Adams, Peter J. Elliott, James F. Holland and Yiyu Zou. Their work appears in journals such as Molecular Pharmacology, The Journal of Steroid Biochemistry and Molecular Biology, Cell Research, Cancer Chemotherapy and Pharmacology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.